Mergers & Acquisitions

Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:

Sell-side Advisory

Leveraging our independence and lack of conflicts, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and give impartial and objective advice about the merits of bids received.

Buy-side Advisory

We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.

Merger Advisory

Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion and a lack of conflicting interests. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.

Special Advisory

Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s independence, experience, expertise and discretion positions us well for special advisory assignments.

Cross-border Advisory

Greenhill’s network of international offices and our ‘single Firm’ operating model allow us to offer clients a seamless cross-border advisory service with a truly global perspective.

Recent Transactions

18-Sep-23
Pending
Undisclosed
France flag
Target: 

Central nervous system (CNS) portfolio from Sanofi

United Kingdom flag
Acquiror: 
Pharmanovia

Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company.

04-Sep-23
Pending
$6.6 billion AUD
Australia flag
Target: 

Liontown Resources Limited

United States flag
Acquiror: 
Albemarle Corporation

Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation.

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

08-Aug-23
Pending
Undisclosed
Spain flag
Target: 

Farmalider Group

Spain flag
Acquiror: 
MCH

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

21-Jul-23
Undisclosed
France flag
Target: 

Synfonium / Qwant / Shadow

France flag
Acquiror: 
Caisse des Dépôts et Consignations (CDC) / Banque des Territoires

Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%

Pages

show all